Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Syon Capital LLC

Syon Capital LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 27.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 782 shares of the biopharmaceutical company’s stock after purchasing an additional 168 shares during the quarter. Syon Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $687,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Stifel Financial Corp lifted its position in Regeneron Pharmaceuticals by 12.2% during the third quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock worth $25,537,000 after buying an additional 3,385 shares during the period. LPL Financial LLC increased its position in Regeneron Pharmaceuticals by 9.3% during the third quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock worth $33,522,000 after purchasing an additional 3,479 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $749,000. Public Employees Retirement Association of Colorado raised its stake in Regeneron Pharmaceuticals by 16.0% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 16,074 shares of the biopharmaceutical company’s stock worth $14,118,000 after purchasing an additional 2,220 shares during the period. Finally, Exchange Traded Concepts LLC raised its stake in Regeneron Pharmaceuticals by 32.7% during the fourth quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock worth $4,351,000 after purchasing an additional 1,221 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on REGN shares. Sanford C. Bernstein started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price on the stock. Morgan Stanley boosted their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. Royal Bank of Canada raised their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,229.00 and gave the company an “outperform” rating in a report on Wednesday. Evercore ISI began coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price target on the stock. Finally, StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. One research analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $991.18.

Insider Transactions at Regeneron Pharmaceuticals

In related news, CEO Leonard S. Schleifer sold 25,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the transaction, the chief executive officer now owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Leonard S. Schleifer sold 787 shares of the company’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $1,015.02, for a total value of $798,820.74. Following the transaction, the chief executive officer now owns 64,198 shares in the company, valued at approximately $65,162,253.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Leonard S. Schleifer sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the sale, the chief executive officer now owns 408,200 shares of the company’s stock, valued at $399,729,850. The disclosure for this sale can be found here. Insiders sold a total of 59,680 shares of company stock valued at $58,818,382 in the last three months. 7.48% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded up $9.97 during midday trading on Friday, hitting $1,036.52. 353,915 shares of the stock were exchanged, compared to its average volume of 364,879. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $114.21 billion, a price-to-earnings ratio of 30.62, a P/E/G ratio of 2.14 and a beta of 0.13. The business has a 50-day moving average price of $956.29 and a two-hundred day moving average price of $935.63. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $1,042.66.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). The business had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.